General inclusion criteria for both groups:
- Positive skin prick test with the positive control (Histamine HCl at 10 mg/mL). The length of the largest diameter of the wheal induced by this control should be ≥ 3 mm.
- Negative skin prick test with the negative control. The length of the largest diameter of the wheal induced by this control should be < 3 mm.
- All ages and both genders.
For the group of patients CH+ (true positive to Betula verrucosa): All these patients had a previous diagnosis of allergy to the birch pollen:
- A positive case history with inhalant allergy related to exposure to birch pollen.
- A positive skin prick test (mean wheal diameter ≥ 3 mm) when tested with a biologically standardized extract prepared from birch pollen. This preparation, from another manufacturer, was the one used in the routine in the Hospital.
- Positive test for specific IgE (CAP value > 0.35 IU/mL). For the group of patients CH- (true negative to Betula verrucosa): All these patients had a previous diagnosis of allergy to agents unrelated to birch pollen.
- A negative case history with inhalant allergy related to exposure to birch pollen or to pollen with known cross-reactivity with the birch pollen. These patients could be allergic to other pollen or other allergens, such mites.
- A negative prick test (largest diameter of the wheal ≥ 3 mm) when tested with a standardized extract prepared from the allergen source in question.
- A negative test for specific IgE (CAP value < 0.35 IU/mL) to birch pollen or to pollen with known cross-reactivity with birch pollen: Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa.
Exclusion criteria for both groups:
- Patients that were using drugs that may interfere with the skin prick tests.
- Patients using the following drugs 24 hours before the test: theophylline, systemic corticosteroids.
- Patients in which the largest diameter of the wheal induced by the positive control was < 3 mm.
- Patients in which the largest diameter of the wheal induced by the negative control was ≥ 3 mm.
- Pregnancy, dermographism, atopic dermatitis (locally at the test site), urticaria.
- Patients who suffer disease in which the use of adrenaline is not allowed.
- Patients with any severe psychiatric disease.
For the patients CH+:
• Patients that received or are treated with immunotherapy with an allergenic extract of birch pollen and/or with allergen extracts with known cross-reactivity to birch pollen (Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa).
For the patients CH-:
- Patients sensitized to pollen with demonstrated cross-reactivity with the pollen of Betula verrucosa. These pollen included Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa.